Roche disclosed Phase 2 data showing its dual GLP‑1/GIP agonist CT‑388 produced a 22.5% placebo‑adjusted weight loss at 48 weeks in people with obesity, and announced plans to advance the asset into Phase 3 testing by the end of March. The results, comparable in magnitude to some existing GLP‑1 regimens in mid‑stage trials, validate Roche’s strategic acquisition of Carmot Therapeutics and its push into the obesity market. The company emphasized the need for additional studies to define commercial positioning against incumbents like Novo Nordisk and Eli Lilly, and signaled combo strategies may be needed to prove long‑term differentiation. The readout intensifies competition in a market already drawing massive investment and regulatory focus.